Clinical Trial Update: Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating neoadjuvant Cadonilimab in combination with Anlotinib for locally advanced resectable esophageal squamous cell carcinoma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Cadonilimab

Snippet

Sponsor: Peking University People's Hospital | Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING